CXCR4 is a major receptor for CXCL12 and is known to participate in multiple physiological systems. The present study tested a second generation CXCR4 antagonist,
AMD3465, for effects on highly defined models of Th1- and Th2-cell-mediated
hypersensitivity-type pulmonary
granuloma formation. Type-1 and type-2
granulomas were induced, respectively, by intravenous challenge of sensitized CBA/J mice with Mycobacteria bovis purified
protein derivative- or Schistosoma mansoni egg
antigen-coated beads. Before challenge, mice were implanted with osmotic pumps releasing
AMD3465 at 5 microg/hour (6 mg/kg/day). Compared to vehicle,
AMD3465 had minimal effect on type-1
inflammation or
cytokine responses in draining lymph nodes, but the type-2
inflammation was significantly abrogated with reductions in lesion size and eosinophil content as well as abrogated
interleukin (IL)-5,
IL-10, and
IL-13 cytokine production in draining lymph nodes. The biased effect of
AMD3465 correlated with greater CXCR4
ligand expression in the type-2 model. Treatment during a primary response impaired lymph node
IL-2 production after both Mycobacteria bovis purified
protein derivative and Schistosoma mansoni egg
antigen challenge indicating an unbiased effect during immune induction. In summary, CXCR4 blockade inhibited eosinophil recruitment during type-2
granuloma formation and interfered with primary and secondary T-cell activation events in lymphoid tissue, suggesting potential therapeutic application for chronic
hypersensitivity diseases.